At a glance
- Originator Praecis Pharmaceuticals
- Class Antirheumatics; Branched-chain amino acids; Epoxy compounds; Essential amino acids
- Mechanism of Action Angiogenesis inhibitors; Methionine aminopeptidase 2 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cancer; Non-Hodgkin's lymphoma; Rheumatoid arthritis; Solid tumours
Most Recent Events
- 16 Feb 2007 Praecis Pharmaceuticals has been acquired by GlaxoSmithKline
- 07 Dec 2006 Data presented at the 18th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics (EORTC-NCI-AACR-2006) added to the adverse events, pharmacokinetics and Cancer pharmacodynamics and therapeutic trials sections
- 14 Mar 2006 This compound is still in active development